A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

590

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Certolizumab Pegol

Trial Locations (70)

Unknown

Montgomery

Sun City West

Palm Desert

Pasadena

Santa Maria

Naples

Palm Harbor

South Miami

New Orleans

St Louis

New Brunswick

Stratford

New York

Rochester

Canfield

Wynnewood

San Antonio

Pleven

Sofia

Stara Zagora

Santiago

Temuco

Rijeka

Brno

Hlučín

Ostrava-Poruba

Prague

Sokolov

UherskeHradiste

Zlín

Tallinn

Afula

Ashkelon

Beer Yaakov

Haifa

Jerusalem

Ramat Gan

Rehovot

Daugavpils

Riga

Alytus

Kaunas

Klaipėda

Panevezys

Šiauliai

D. F.

Mexicalli

México

Monterrey

Tijuana

Bialystok

Elblag

Krakow

Lublin

Sopot

Torun

Moscow

Saint Petersburg

Yaroslavl

Belgrade

Niška Banja

Novi Sad

Košice

Piešťany

Dnipro

Donetsk

Ivano-Frankivsk

Kiev

Simferopol

Zaporizhzhya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY